Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.

Autor: Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany., Pratz KW; Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Wei AH; Department of Clinical Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and The University of Melbourne, Melbourne, Australia., Jonas BA; Division of Malignant Hematology/Cellular Therapy and Transplantation, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA., Pullarkat VA; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA., Thirman MJ; Department of Medicine, Section of Hematology and Oncology, University of Chicago Medicine, Chicago, IL., Récher C; Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France., Schuh AC; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Babu S; Division of Clinical Research, Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN., Li X; AbbVie Inc, North Chicago, IL., Ku G; Genentech Inc, South San Francisco, CA., Liu Z; AbbVie Inc, North Chicago, IL., Sun Y; AbbVie Inc, North Chicago, IL., Potluri J; AbbVie Inc, North Chicago, IL., Dail M; Genentech Inc, South San Francisco, CA., Chyla B; AbbVie Inc, North Chicago, IL., Pollyea DA; Division of Hematology, School of Medicine, University of Colorado, Aurora, CO.

Publikováno v: Blood [Blood] 2024 Nov 21; Vol. 144 (21), pp. 2211-2222.

Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma

Autor: Schjesvold, F. (Fredrik), Lourenco-Paiva, B. (Bruno David), Ribrag, V. (Vincent), Rodríguez-Otero, P. (Paula), San-Miguel-Izquierdo, J. (Jesús Fernando), Robak, P. (Pawel), Hansson, M. (Markus), Onishi, M. (Maika), Hamidi, H. (Habib), Malhi, V. (Vikram), Dail, M., Dail, M. (Monique), Javery, A. (Apurva), Ku, G. (Grace), Raab, M. S. (Marc S.)

This phase IB/II trial evaluated safety and efficacy of cobimetinib alone and in novel combinations with veneto-clax with/without atezolizumab in patients with relapsed/refractory multiple myeloma. Forty-nine patients were enrolled. Cobimetinib alone

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1111::d767d93ffafae145a8ea7c5feb487593
https://hdl.handle.net/10171/66017

Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.

Autor: Wandler AM; Department of Pediatrics, University of California, San Francisco, CA, USA., Huang BJ; Department of Pediatrics, University of California, San Francisco, CA, USA., Craig JW; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Hayes K; Department of Pediatrics, University of California, San Francisco, CA, USA., Yan H; Department of Pediatrics, University of California, San Francisco, CA, USA., Meyer LK; Department of Pediatrics, University of California, San Francisco, CA, USA., Scacchetti A; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA., Monsalve G; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA., Dail M; Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA., Li Q; Department of Medicine, University of Michigan, Ann Arbor, MI, USA., Wong JC; Department of Pediatrics, University of California, San Francisco, CA, USA., Weinberg O; Department of Pathology, Boston Children's Hospital, Boston, MA, USA., Hasserjian RP; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Kogan SC; Department of Laboratory Medicine, University of California, San Francisco, CA, USA., Jonsson P; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yamamoto K; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA., Sampath D; Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA., Nakitandwe J; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA., Downing JR; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA., Zhang J; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Aster JC; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Taylor BS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shannon K; Department of Pediatrics, University of California, San Francisco, CA, USA. kevin.shannon@ucsf.edu.

Publikováno v: Leukemia [Leukemia] 2020 Aug; Vol. 34 (8), pp. 2025-2037. Date of Electronic Publication: 2020 Feb 17.

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.

Autor: Daver NG; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Dail M; Genentech, Inc, South San Francisco, CA., Garcia JS; Dana-Farber Cancer Institute, Boston, MA., Jonas BA; University of California Davis Comprehensive Cancer Center, Sacramento, CA., Yee KWL; Princess Margaret Cancer Centre, Toronto, ON, Canada., Kelly KR; Division of Hematology, University of Southern California, Los Angeles, CA., Vey N; Hematologie Clinique, Institut Paoli-Calmettes, Marseille, France., Assouline S; Jewish General Hospital, Montreal, QC, Canada., Roboz GJ; Weill Cornell Medical College, New York Presbyterian, New York, NY., Paolini S; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy., Pollyea DA; Division of Hematology, School of Medicine, University of Colorado, Aurora, CO., Tafuri A; Hematology, Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea-Sapienza, Rome, Italy., Brandwein JM; Division of Hematology, University of Alberta, Edmonton, AB, Canada., Pigneux A; Bordeaux Haut-Lévêque University Hospital, Pessac, France., Powell BL; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC., Fenaux P; Hôpital Saint-Louis, Université Paris Diderot, Paris, France., Olin RL; University of California San Francisco, San Francisco, CA., Visani G; Hematology, Ospedale San Salvatore, Pesaro, Italy., Martinelli G; IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori,' Meldola, Italy., Onishi M; Genentech, Inc, South San Francisco, CA., Wang J; Genentech, Inc, South San Francisco, CA., Huang W; Genentech, Inc, South San Francisco, CA., Green C; Genentech, Inc, South San Francisco, CA., Ott MG; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Hong WJ; Imago BioSciences, South San Francisco, CA., Konopleva MY; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Andreeff M; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publikováno v: Blood [Blood] 2023 Mar 16; Vol. 141 (11), pp. 1265-1276.

Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma.

Autor: Schjesvold F; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway. Electronic address: fredrikschjesvold@gmail.com., Paiva B; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain., Ribrag V; Institut Gustave Roussy, Villejuif, France., Rodriguez-Otero P; Clínica Universidad de Navarra, CCUN, University of Navarra, Pamplona, Spain., San-Miguel JF; Clínica Universidad de Navarra, CCUN, University of Navarra, Pamplona, Spain., Robak P; Medical University of Lodz, Lodz, Poland., Hansson M; Skane University Hospital, Lund, Sweden and Sahlgrenska Academy, Gothenburg, Sweden., Onishi M; Genentech, Inc, South San Francisco, CA., Hamidi H; Genentech, Inc, South San Francisco, CA., Malhi V; Genentech, Inc, South San Francisco, CA., Dail M; Genentech, Inc, South San Francisco, CA., Javery A; Syneos Health, Raleigh, Raleigh, NC., Ku G; Genentech, Inc, South San Francisco, CA., Raab MS; Heidelberg University Hospital, Department of Medicine V, Heidelberg, Germany.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Jan; Vol. 23 (1), pp. e59-e70. Date of Electronic Publication: 2022 Oct 22.